Citrate versus heparin anticoagulation for pediatric continuous renal replacement therapy
Phase 3
Recruiting
- Conditions
- Pediatric intensive care patientsContinuous renal replacement therapyContinuous renal replacement therapyChildren
- Registration Number
- TCTR20230421001
- Lead Sponsor
- Suvikrom Law
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
1. Children aged 1-18 years who are admitted to PICU, 2. Plan to receive continuous renal replacement therapy
Exclusion Criteria
1. Coagulopathy (INR >/= 2), 2. Platelet < 50000/mm3, 3. Heparin induced thrombocytopenia (HIT) or history of HIT, 4. Active bleeding, 5. Receiving heparin or low molecular weight heparin in therapeutic dose, 6. Pregnancy or lactation, 7. Heparin allergy, 8. Serum lactate > 5 mmol/l, 9. On ECMO
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Circuit life During CRRT treatment Time from starting CRRT circuit until stop due to circuit clotting, measured in minutes
- Secondary Outcome Measures
Name Time Method Citrate accumulation Measured every 6 hours during CRRT Total/ionized Ca ratio more than 2.5,Metabolic alkalosis Measured every 6 hours during CRRT pH above 7.50 and HCO3 above 30,Bleeding During CRRT treatment Direct observation,Heparin induced thrombocytopenia During CRRT treatment Platelet count and antibody